| CAS | 1815618-06-4 |
| Sequence | Biotinyl-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Disulfide bond) |
| Sequence Single | Biotinyl-SLRRSSCFGGRMDRIGAQSGLGCNSFRY |
| Molecular Formula | C137H217N47O41S4 |
| Molecular Weight | 3306.75 |
| Synonyms | Biotinyl-carperitide, Biotin-Atrial Natriuretic Peptide (1-28), human, porcine |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Biotinylated Peptides|Cardiovascular System & Diseases |
| Description | Biotinyl-Atrial Natriuretic Factor (1-28) (human) also called Biotinyl-carperitide, Biotin-Atrial Natriuretic Peptide (1-28), human, porcine, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research. |
| References | 1. Natriuretic peptide drug leads from snake venom. S Vink, et al. 2012 Mar 15;59(4):434-45. 2. Participation of glucose transporters on atrial natriuretic peptide-induced glucose uptake by adult and neonatal cardiomyocytes under oxygenation and hypoxia. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Verónica Sosa, et al. Eur J Pharmacol. 2007 Jul 30;568(1-3):83-8. |